IBDEI0MO ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,10190,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10190,1,3,0)
 ;;=3^DM Type 1 w/ Periph Angiopathy w/o Gangrene
 ;;^UTILITY(U,$J,358.3,10190,1,4,0)
 ;;=4^E10.51
 ;;^UTILITY(U,$J,358.3,10190,2)
 ;;=^5002610
 ;;^UTILITY(U,$J,358.3,10191,0)
 ;;=E10.52^^39^430^31
 ;;^UTILITY(U,$J,358.3,10191,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10191,1,3,0)
 ;;=3^DM Type 1 w/ Periph Angiopathy w/ Gangrene
 ;;^UTILITY(U,$J,358.3,10191,1,4,0)
 ;;=4^E10.52
 ;;^UTILITY(U,$J,358.3,10191,2)
 ;;=^5002611
 ;;^UTILITY(U,$J,358.3,10192,0)
 ;;=E11.00^^39^431^19
 ;;^UTILITY(U,$J,358.3,10192,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10192,1,3,0)
 ;;=3^DM Type 2 w/ Hyperosmolarity w/o NKHHC
 ;;^UTILITY(U,$J,358.3,10192,1,4,0)
 ;;=4^E11.00
 ;;^UTILITY(U,$J,358.3,10192,2)
 ;;=^5002627
 ;;^UTILITY(U,$J,358.3,10193,0)
 ;;=E11.01^^39^431^18
 ;;^UTILITY(U,$J,358.3,10193,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10193,1,3,0)
 ;;=3^DM Type 2 w/ Hyperosmolarity w/ Coma
 ;;^UTILITY(U,$J,358.3,10193,1,4,0)
 ;;=4^E11.01
 ;;^UTILITY(U,$J,358.3,10193,2)
 ;;=^5002628
 ;;^UTILITY(U,$J,358.3,10194,0)
 ;;=E11.21^^39^431^7
 ;;^UTILITY(U,$J,358.3,10194,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10194,1,3,0)
 ;;=3^DM Type 2 w/ Diab Nephropathy
 ;;^UTILITY(U,$J,358.3,10194,1,4,0)
 ;;=4^E11.21
 ;;^UTILITY(U,$J,358.3,10194,2)
 ;;=^5002629
 ;;^UTILITY(U,$J,358.3,10195,0)
 ;;=E11.22^^39^431^3
 ;;^UTILITY(U,$J,358.3,10195,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10195,1,3,0)
 ;;=3^DM Type 2 w/ Diab CKD
 ;;^UTILITY(U,$J,358.3,10195,1,4,0)
 ;;=4^E11.22
 ;;^UTILITY(U,$J,358.3,10195,2)
 ;;=^5002630
 ;;^UTILITY(U,$J,358.3,10196,0)
 ;;=E11.39^^39^431^28
 ;;^UTILITY(U,$J,358.3,10196,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10196,1,3,0)
 ;;=3^DM Type 2 w/ Oth Diab Ophth Compl
 ;;^UTILITY(U,$J,358.3,10196,1,4,0)
 ;;=4^E11.39
 ;;^UTILITY(U,$J,358.3,10196,2)
 ;;=^5002643
 ;;^UTILITY(U,$J,358.3,10197,0)
 ;;=E11.41^^39^431^6
 ;;^UTILITY(U,$J,358.3,10197,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10197,1,3,0)
 ;;=3^DM Type 2 w/ Diab Mononeuropathy
 ;;^UTILITY(U,$J,358.3,10197,1,4,0)
 ;;=4^E11.41
 ;;^UTILITY(U,$J,358.3,10197,2)
 ;;=^5002645
 ;;^UTILITY(U,$J,358.3,10198,0)
 ;;=E11.42^^39^431^13
 ;;^UTILITY(U,$J,358.3,10198,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10198,1,3,0)
 ;;=3^DM Type 2 w/ Diab Polyneuropathy
 ;;^UTILITY(U,$J,358.3,10198,1,4,0)
 ;;=4^E11.42
 ;;^UTILITY(U,$J,358.3,10198,2)
 ;;=^5002646
 ;;^UTILITY(U,$J,358.3,10199,0)
 ;;=E11.43^^39^431^2
 ;;^UTILITY(U,$J,358.3,10199,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10199,1,3,0)
 ;;=3^DM Type 2 w/ Diab Autonomic Polyneuropathy
 ;;^UTILITY(U,$J,358.3,10199,1,4,0)
 ;;=4^E11.43
 ;;^UTILITY(U,$J,358.3,10199,2)
 ;;=^5002647
 ;;^UTILITY(U,$J,358.3,10200,0)
 ;;=E11.44^^39^431^1
 ;;^UTILITY(U,$J,358.3,10200,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10200,1,3,0)
 ;;=3^DM Type 2 w/ Diab Amyotrophy
 ;;^UTILITY(U,$J,358.3,10200,1,4,0)
 ;;=4^E11.44
 ;;^UTILITY(U,$J,358.3,10200,2)
 ;;=^5002648
 ;;^UTILITY(U,$J,358.3,10201,0)
 ;;=E11.49^^39^431^8
 ;;^UTILITY(U,$J,358.3,10201,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10201,1,3,0)
 ;;=3^DM Type 2 w/ Diab Neurological Compl
 ;;^UTILITY(U,$J,358.3,10201,1,4,0)
 ;;=4^E11.49
 ;;^UTILITY(U,$J,358.3,10201,2)
 ;;=^5002649
 ;;^UTILITY(U,$J,358.3,10202,0)
 ;;=E11.59^^39^431^25
 ;;^UTILITY(U,$J,358.3,10202,1,0)
 ;;=^358.31IA^4^2
